Association of miR-608 rs4919510 polymorphism and cancer risk: a meta-analysis based on 13,664 subjects

Liu, Huiquan; Zhou, Ya‐Qun; Liu, Qingquan; Xiao, Guangqin; Wang, Bangyan; Li, Weijuan; Ye, Dawei; Yu, Shiying

doi:10.18632/oncotarget.9509

Cited by 15 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been proposed that rs4919510 C>G variant in miR-608 can alter its binding to target genes. MiR-608 expectedly targets growth hormone receptor (GHR), interleukin-1 alpha (IL1A), insulin receptor (INSR), and TP53[ 7 – 9 ]. Several studies examined the impacts of miR-608 rs4919510 C>G on breast cancers risks, but the results were inconsistent[ 8 , 10 – 13 ].…”

Section: Introductionmentioning

confidence: 99%

A meta-analysis: Is there any association between MiR-608 rs4919510 polymorphism and breast cancer risks?

et al. 2017

View full text Add to dashboard Cite

ObjectTo combine the data from previously conducted studies about the associations between miR-608 rs4919510 polymorphism (C>G) and breast cancer risks.MethodsAccording to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a systematic review of the related literatures searched from PubMed, Embase, Cochrane Library, Web of Science, and China National Knowledge Internet (CNKI) (time: ~ December 2016). Using DerSimonian-Laird random-effects models [Pooling Model: Mantel Haenszel (MH)], odd ratios (ORs) with 95% confidence intervals (95% CIs) were estimated in the allele model, homozygote model, heterozygote model, dominant model and recessive model. Heterogeneity was analyzed using Labbr plots and I2 statistic. Publication bias was analyzed using contour-enhanced funnel plots.ResultsWe included 5 eligible studies with 7948 patients. The ORs and their 95% CIs in the 5 genetic models mentioned above were 1.009 (95% CI: 0.922, 1.104; p = 0.847), 1.098 (95% CI: 0.954, 1.264; p = 0.194), 1.076 (95% CI: 0.956, 1.211; p = 0.227), 1.043 (95% CI: 0.880, 1.236; p = 0.628), 1.007 (95% CI: 0.906, 1.118; p = 0.899), respectively.ConclusionIn the present meta-analysis, no relationships between miR-608 rs4919510 polymorphism (C>G) and the risk of breast cancer were found. More studies are warranted to further validate the conclusion.

show abstract

Section: Introductionmentioning

confidence: 99%

A meta-analysis: Is there any association between MiR-608 rs4919510 polymorphism and breast cancer risks?

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In literature, there are numerous reports describing cancer risk association with SNPs related to microRNAs life. In a meta-analysis by Liu and colleagues (Liu H. et al, 2017 ), conducted on ten studies with 6,000 cases and 7,664 controls, a significant association of miR-608 rs4919510 polymorphism with decreased cancer risk via recessive model (CC vs. GG + GC) was found. Interestingly, the same polymorphism has been already described to predict the clinical outcome in patients with different cancer types (Lin et al, 2012 ; Zheng et al, 2013 ; Pardini et al, 2015 ).…”

Section: Mirsnpmentioning

confidence: 99%

microRNAs Make the Call in Cancer Personalized Medicine

Detassis

Grasso

Vescovo

et al. 2017

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Since their discovery and the advent of RNA interference, microRNAs have drawn enormous attention because of their ubiquitous involvement in cellular pathways from life to death, from metabolism to communication. It is also widely accepted that they possess an undeniable role in cancer both as tumor suppressors and tumor promoters modulating cell proliferation and migration, epithelial-mesenchymal transition and tumor cell invasion and metastasis. Moreover, microRNAs can even affect the tumor surrounding environment influencing angiogenesis and immune system activation and recruitment. The tight association of microRNAs with several cancer-related processes makes them undoubtedly connected to the effect of specific cancer drugs inducing either resistance or sensitization. In this context, personalized medicine through microRNAs arose recently with the discovery of single nucleotide polymorphisms in the target binding sites, in the sequence of the microRNA itself or in microRNA biogenesis related genes, increasing risk, susceptibility and progression of multiple types of cancer in different sets of the population. The depicted scenario implies that the overall variation displayed by these small non-coding RNAs have an impact on patient-specific pharmacokinetics and pharmacodynamics of cancer drugs, pushing on a rising need of personalized treatment. Indeed, microRNAs from either tissues or liquid biopsies are also extensively studied as valuable biomarkers for disease early recognition, progression and prognosis. Despite microRNAs being intensively studied in recent years, a comprehensive review describing these topics all in one is missing. Here we report an up-to-date and critical summary of microRNAs as tools for better understanding personalized cancer biogenesis, evolution, diagnosis and treatment.

show abstract

“…Several studies have shown the importance of single nucleotide polymorphisms (SNPs) for the risk of cancer development. Such SNPs are located either in genes involved in microRNA biogenesis or inside microRNA binding sites (MBS) at the target mRNA [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Genetic variation of the gene coding for microRNA-204 (miR-204) is a risk factor in acute myeloid leukaemia

et al. 2018

View full text Add to dashboard Cite

BackgroundMicroRNAs (miRNAs or miRs) are small molecules known to be involved in post-transcriptional gene expression. Many of them have been shown to influence risk for various diseases. Recent studies suggest that lower expression of miR-204, a gene coding for miRNA-204, is correlated with shorter survival in patients with acute myeloid leukaemia (AML). This observation prompted us to analyse the effect of two polymorphisms of the miR-204 gene, one in the upstream flanking region (rs718447 A > G) and the other inside the gene itself (rs112062096 A > G), both also in intron 3 of the TRPM3 gene.MethodsThe study was conducted on DNA samples isolated from AML patients (n = 95) and healthy individuals (n = 148), who were genotyped using the Light SNiP assays.ResultsThe miR-204 rs718447 GG homozygosity was found to constitute a risk factor associated with susceptibility to AML (73/95 vs 92/148, AML patients vs healthy controls, OR = 2.020, p = 0.017). Additionally, this genotype was more frequent in patients with subtypes M0-M1 in the French-American-British (FAB) classification as compared to patients with subtypes M2-M7 (23/25 vs 39/57, p = 0.026). We also found that presence of allele A was linked to longer survival of AML patients.ConclusionsOur results show that polymorphism in miR-204 flanking region may constitute a risk and prognostic factor in AML.

show abstract

Association of miR-608 rs4919510 polymorphism and cancer risk: a meta-analysis based on 13,664 subjects

Cited by 15 publications

References 34 publications

A meta-analysis: Is there any association between MiR-608 rs4919510 polymorphism and breast cancer risks?

A meta-analysis: Is there any association between MiR-608 rs4919510 polymorphism and breast cancer risks?

microRNAs Make the Call in Cancer Personalized Medicine

Genetic variation of the gene coding for microRNA-204 (miR-204) is a risk factor in acute myeloid leukaemia

Contact Info

Product

Resources

About